{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:23:39Z","timestamp":1781763819269,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-143350"],"award-info":[{"award-number":["FDN-143350"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006506","name":"Minist\u00e9rio da Sa\u00fade","doi-asserted-by":"publisher","award":["NUP 25000.012788\/2021-61"],"award-info":[{"award-number":["NUP 25000.012788\/2021-61"]}],"id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The World Health Organization recommends tuberculosis (TB) preventive treatment (TPT) for all people living with HIV (PLH) and household contacts (HHC) of index TB patients. Tests for TB infection (TBI) or to rule out TB disease (TBD) are preferred, but if not available, this should not be a barrier if access to these tests is limited for high-risk people, such as PLH and HHC under 5\u00a0years old. There is equipoise on the need for these tests in different risk populations, especially HHC aged over 5.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This superiority cluster-randomized multicenter trial with three arms of equal size compares, in Benin and Brazil, three strategies for HHC investigation aged 0\u201350: (i) tuberculin skin testing (TST) or interferon gamma release assay (IGRA) for TBI and if positive, chest X-Ray (CXR) to rule out TBD in persons with positive TST or IGRA; (ii) same as (i) but GeneXpert (GX) replaces CXR; and (iii) no TBI testing. CXR for all; if CXR is normal, TPT is recommended. All strategies start with symptom screening. Clusters are defined as HHC members of the same index patients with newly diagnosed pulmonary TBD. The main outcome is the proportion of HHC that are TPT eligible who start TPT within 3\u00a0months of the index TB patient starting TBD treatment. Societal costs, incidence of severe adverse events, and prevalence of TBD are among secondary outcomes. Stratified analyses by age (under versus over 5) and by index patient microbiological status will be conducted.<\/jats:p>\n                <jats:p>All participants provide signed informed consent. The study was approved by the Research Ethic Board of the Research Institute of the McGill University Health Centre, the Brazilian National Ethical Board CONEP, and the \u201cComit\u00e9 Local d\u2019\u00c9thique Pour la Recherche Biom\u00e9dicale (CLERB) de l\u2019Universit\u00e9 de Parakou,\u201d Benin. Findings will be submitted for publication in major medical journals and presented in conferences, to WHO and National and municipal TB programs of the involved countries.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This randomized trial is meant to provide high-quality evidence to inform WHO recommendations on investigation of household contacts, as currently these are based on very low-quality evidence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov NCT04528823.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06587-0","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T09:06:23Z","timestamp":1659431183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GeneXpert or chest-X-ray or tuberculin skin testing for household contact assessment (GXT): protocol for a cluster-randomized trial"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4000-4984","authenticated-orcid":false,"given":"Anete","family":"Trajman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menonli","family":"Adjobimey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayara Lisboa","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Valiquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Oxlade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fregonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dissou","family":"Affolabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Cordeiro-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato T.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"6587_CR1","volume-title":"Global tuberculosis report 2021","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"6587_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1146\/annurev-publhealth-031912-114431","volume":"34","author":"C Dye","year":"2013","unstructured":"Dye C, Glaziou P, Floyd K, et al. Prospects for tuberculosis elimination. Annu Rev Public Health. 2013;34:271\u201386. https:\/\/doi.org\/10.1146\/annurev-publhealth-031912-114431.","journal-title":"Annu Rev Public Health"},{"key":"6587_CR3","doi-asserted-by":"publisher","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RMGJ Houben","year":"2016","unstructured":"Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13:e1002152. https:\/\/doi.org\/10.1371\/journal.pmed.1002152.","journal-title":"PLoS Med"},{"key":"6587_CR4","unstructured":"WHO consolidated guidelines on tuberculosis. Module 1: prevention \u2013 tuberculosis preventive\u00a0treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. Available at https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1270183\/retrieve."},{"key":"6587_CR5","volume-title":"WHO consolidated guidelines on tuberculosis. Module 1, Prevention: tuberculosis preventive treatment","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1, Prevention: tuberculosis preventive treatment. 2020."},{"key":"6587_CR6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","volume":"16","author":"H Alsdurf","year":"2016","unstructured":"Alsdurf H, Hill PC, Matteelli A, et al. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16:1269\u201378. https:\/\/doi.org\/10.1016\/S1473-3099(16)30216-X.","journal-title":"Lancet Infect Dis"},{"key":"6587_CR7","doi-asserted-by":"publisher","first-page":"m549","DOI":"10.1136\/bmj.m549","volume":"368","author":"JR Campbell","year":"2020","unstructured":"Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020;368:m549. https:\/\/doi.org\/10.1136\/bmj.m549.","journal-title":"BMJ"},{"issue":"4","key":"6587_CR8","doi-asserted-by":"publisher","first-page":"e00423","DOI":"10.1002\/prp2.423","volume":"6","author":"M Russom","year":"2018","unstructured":"Russom M, Debesai M, Zeregabr M, et al. Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea. Pharmacol Res Perspect. 2018;6(4):e00423. https:\/\/doi.org\/10.1002\/prp2.423.","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"6587_CR9","doi-asserted-by":"publisher","first-page":"CD001363","DOI":"10.1002\/14651858.CD001363","volume":"1999","author":"MJ Smieja","year":"2000","unstructured":"Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000;1999(2):CD001363. https:\/\/doi.org\/10.1002\/14651858.CD001363.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"6587_CR10","doi-asserted-by":"publisher","first-page":"CD000171","DOI":"10.1002\/14651858.CD000171.pub3","volume":"2010","author":"C Akolo","year":"2010","unstructured":"Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;2010(1):CD000171. https:\/\/doi.org\/10.1002\/14651858.CD000171.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"6587_CR11","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","volume":"377","author":"T Samandari","year":"2011","unstructured":"Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:1588\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(11)60204-3.","journal-title":"Lancet"},{"key":"6587_CR12","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1507198","volume":"373","author":"The TEMPRANO ANRS 12136 Study Group","year":"2015","unstructured":"The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. NEJM. 2015;373:808\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1507198.","journal-title":"NEJM"},{"key":"6587_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1183\/09031936.00070812","volume":"41","author":"GJ Fox","year":"2013","unstructured":"Fox GJ, Barry SE, Britton WJ, et al. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41:140\u201356. https:\/\/doi.org\/10.1183\/09031936.00070812.","journal-title":"Eur Respir J"},{"key":"6587_CR14","doi-asserted-by":"publisher","first-page":"e1003703","DOI":"10.1371\/journal.pmed.1003703","volume":"18","author":"ML Bastos","year":"2021","unstructured":"Bastos ML, Melnychuk L, Campbell JR, et al. The latent tuberculosis cascade-of-care among people living with HIV: a systematic review and meta-analysis. PLoS Med. 2021;18:e1003703. https:\/\/doi.org\/10.1371\/journal.pmed.1003703.","journal-title":"PLoS Med"},{"key":"6587_CR15","doi-asserted-by":"publisher","first-page":"e1000391","DOI":"10.1371\/journal.pmed.1000391","volume":"8","author":"H Getahun","year":"2011","unstructured":"Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8:e1000391. https:\/\/doi.org\/10.1371\/journal.pmed.1000391.","journal-title":"PLoS Med"},{"key":"6587_CR16","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1016\/S2352-3018(18)30137-1","volume":"5","author":"Y Hamada","year":"2018","unstructured":"Hamada Y, Lujan J, Schenkel K, et al. Sensitivity and specificity of WHO\u2019s recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5:e515\u201323. https:\/\/doi.org\/10.1016\/S2352-3018(18)30137-1.","journal-title":"Lancet HIV"},{"key":"6587_CR17","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1016\/S2352-3018(18)30213-3","volume":"5","author":"C Hanrahan","year":"2018","unstructured":"Hanrahan C, Dowdy D. Chest X-ray for tuberculosis preventive therapy: use caution. Lancet HIV. 2018;5:e478\u20139. https:\/\/doi.org\/10.1016\/S2352-3018(18)30213-3.","journal-title":"Lancet HIV"},{"key":"6587_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.5588\/ijtld.15.0908","volume":"20","author":"S den Boon","year":"2016","unstructured":"den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20:1065\u201371. https:\/\/doi.org\/10.5588\/ijtld.15.0908.","journal-title":"Int J Tuberc Lung Dis"},{"key":"6587_CR19","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3201\/eid1205.050681","volume":"12","author":"ME Balcells","year":"2006","unstructured":"Balcells ME, Thomas SL, Godfrey-Faussett P, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerging Infect Dis. 2006;12:744\u201351. https:\/\/doi.org\/10.3201\/eid1205.050681.","journal-title":"Emerging Infect Dis"},{"key":"6587_CR20","unstructured":"R\u00e9publique du Benin. Minist\u00e8re de la Sant\u00e9. Direction National de la Sant\u00e9 Publique. Programme National contre la Tuberculose. Guide du Programme national contre la Tuberculose. 4\u00e8me edition. 2017. Available at http:\/\/www.pnt-benin.org\/wp-content\/uploads\/2019\/02\/Benin_Guide-PNT.pdf."},{"key":"6587_CR21","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de Vigil\u00e2ncia Epidemiol\u00f3gica. Manual de recomenda\u00e7\u00f5es para o controle da tuberculose no Brasil \/ Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia Epidemiol\u00f3gica. \u2013 Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2011. 284 p. ISBN 978-85-334-1816-5."},{"key":"6587_CR22","doi-asserted-by":"publisher","first-page":"e0215240","DOI":"10.1371\/journal.pone.0215240","volume":"14","author":"S Moayedi-Nia","year":"2019","unstructured":"Moayedi-Nia S, Barss L, Oxlade O, et al. The mTST - an mHealth approach for training and quality assurance of tuberculin skin test administration and reading. PLoS ONE. 2019;14:e0215240. https:\/\/doi.org\/10.1371\/journal.pone.0215240.","journal-title":"PLoS ONE"},{"key":"6587_CR23","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/S2214-109X(13)70036-6","volume":"1","author":"HJ Zar","year":"2013","unstructured":"Zar HJ, Workman L, Isaacs W, et al. Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of Xpert MTB\/RIF on respiratory specimens: a prospective study. Lancet Glob Health. 2013;1:e97-104. https:\/\/doi.org\/10.1016\/S2214-109X(13)70036-6.","journal-title":"Lancet Glob Health"},{"key":"6587_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12913-020-05220-7","volume":"20","author":"H Alsdurf","year":"2020","unstructured":"Alsdurf H, Oxlade O, Adjobimey M, et al. Resource implications of the latent tuberculosis cascade of care: a time and motion study in five countries. BMC Health Serv Res. 2020;20:341. https:\/\/doi.org\/10.1186\/s12913-020-05220-7.","journal-title":"BMC Health Serv Res"},{"key":"6587_CR25","unstructured":"OneHealth Tool software (Avenir Health, Glastonbury, CT, v. 6.19, April 2022). Available at https:\/\/www.avenirhealth.org\/software-onehealth.php."},{"key":"6587_CR26","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.5588\/ijtld.19.0728","volume":"24","author":"ML Bastos","year":"2020","unstructured":"Bastos ML, Oxlade O, Benedetti A, et al. A public health approach to increase treatment of latent TB among household contacts in Brazil. Int J Tuberc Lung Dis. 2020;24:1000\u20138. https:\/\/doi.org\/10.5588\/ijtld.19.0728.","journal-title":"Int J Tuberc Lung Dis"},{"key":"6587_CR27","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/S2468-2667(20)30261-9","volume":"6","author":"O Oxlade","year":"2021","unstructured":"Oxlade O, Benedetti A, Adjobimey M, et al. Effectiveness and cost-effectiveness of a health systems intervention for latent tuberculosis infection management (ACT4): a cluster-randomised trial. The Lancet Public Health. 2021;6:e272\u201382. https:\/\/doi.org\/10.1016\/S2468-2667(20)30261-9.","journal-title":"The Lancet Public Health"},{"key":"6587_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1714284","volume":"379","author":"T Diallo","year":"2018","unstructured":"Diallo T, Adjobimey M, Ruslami R, et al. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018;379:454\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1714284.","journal-title":"N Engl J Med"},{"key":"6587_CR29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","volume":"379","author":"D Menzies","year":"2018","unstructured":"Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379:440\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1714283.","journal-title":"N Engl J Med"},{"key":"6587_CR30","doi-asserted-by":"publisher","unstructured":"Bertram M, Edejer T. Introduction to the Special Issue on \u201cThe World Health Organization Choosing Interventions That Are Cost-Effective (WHOCHOICE) Update\u201d. Int J Health Policy\u00a0Manage. 2021;10(Special Issue on WHOCHOICE Update):670\u20132. https:\/\/doi.org\/10.34172\/ijhpm.2021.105.","DOI":"10.34172\/ijhpm.2021.105"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06587-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06587-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06587-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T09:15:40Z","timestamp":1659431740000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06587-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6587"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06587-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"assertion":[{"value":"16 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants will sign an informed consent obtained by the research team. In Brazil, index TB patients will also sign an informed consent. The current version of the study was approved by the Research Ethic Board of the Research Institute of the McGill University Health Centre on August 16, 2019 (Study 2020\u20135634 Form F1-59915), by the Brazilian National Ethical Board CONEP on May 7, 2020 (#4.014.402), and by the \u201cComit\u00e9 Local d\u2019\u00c9thique Pour la Recherche Biom\u00e9dicale (CLERB) de l\u2019Universit\u00e9 de Parakou,\u201d Benin, on December 30, 2019 (#0293). In Brazil, an amendment to include children under 5 and index TB patients who were clinically diagnosed (not microbiologically confirmed) was approved on July 30, 2021 (#4.133.939).All protocol amendments were approved by the ethical review boards and notified to the funders and subsequently to the centers. A copy of the revised protocol is available in each site\u2019s Master Binder. Any deviations or violations from the protocol are fully documented using a report form (Note to File). All adverse events and deviation are informed to the Coordinating Centre in Montreal. Any serious adverse event is also reported to the ethical review boards.Findings will be submitted for publication in major medical journals and presented in conferences, to WHO and National and municipal TB Programs of the involved countries as reports and in planned workshops. All data is safely stored at . Results will be submitted for publication in major medical journals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"624"}}